In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.
|Articles|June 10, 2015
Marianne Davies Discusses Side Effects Associated With Immunotherapy
Author(s)Marianne Davies, RN, MSN, ACNP, AOCN
Marianne Davies, RN, MSN, ACNP, AOCN, Smilow Cancer Hospital, Yale School of Nursing, discusses the side effects associated with immunotherapy.
Advertisement
Marianne Davies, RN, MSN, ACNP, AOCN, Smilow Cancer Hospital, Yale School of Nursing, discusses the side effects associated with immunotherapy.
Advertisement
Related to this article
In observation of National PA Week, Moffitt PA Mark Honor discusses the expansion of APPs and key collaboration strategies for oncology nurses.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles.
At ASTRO 2026, Suresh Rana details how AI-driven contouring accelerates care timelines, requiring rigorous team monitoring and early nursing input.
At ASTRO 2026, Dr. Erica Braschi Jordan details toxicity tracking, physical therapy referral, and quality of life in proton regional nodal irradiation.
At ASTRO 2026, Dr. Mishaal Munir details how nurse-led triage workflows and prompt symptom escalations improve care for breast cancer brain metastases.
ASTRO 2026 presenter Kayla Kafka-Peterson details an Adapt-Adopt-Build model to bridge global brachytherapy nursing gaps and standardize perioperative care.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Delaying BSO to Age 50 Leaves BRCA1 Carriers With 24% Ovarian Cancer Risk
2
GLP-1s After Breast Cancer: What Nurses Should Ask Survivors
3
Automated Breast Ultrasound Tied to Fewer False-Positives in Dense Breasts
4
Beyond the Treatment Center: Exploring Equine Assisted Wellness
5